Insider trade

Director sold ~$160K of DXCM shares in the open market

Traded Jul 31, 2026 · Filed Aug 4, 2026

DexcomDXCM

~$160K
Reported value · 2,000 sh @ $80.00: 51K
Holds after · shares reported: +3.3%
stock since the trade · S&P 500 +2.3%, $83.45 → $86.23 on Oct 1

Why it stands out

A board member of Dexcom sold $160K of Dexcom shares. It was planned long ago, so it says very little.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Jul 31, 2026
Reporting period: Not applicable
Filed with the SEC: Aug 4, 2026

DirectorIndirect holding$100K–$500KPre-arranged plan referenced

Context

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$160,000

Shares × reported transaction price

Timing vs results

1 day after results of Jul 30, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Price at the time

Closed at $83.45 on Jul 31, 2026, at its 52-week high, after a 17% rise over the previous 30 trading days

52-week range $54.84 (Nov 10, 2025) to $83.45 (Jul 31, 2026), 100% of the way up, from 251 adjusted closes. 30 trading days earlier: $71.23 on Jun 17, 2026. Describes the past only, not a forecast

Planned / mechanical clue

Footnote references a pre-arranged trading plan (Rule 10b5-1)

Only flagged when a footnote says so; never inferred

Securities lawsuit open at the trade date

A securities lawsuit naming the company as a defendant was filed on Oct 27, 2025 in the U.S. District Court, S.D. New York. A filing is an allegation, not a finding.

4 such cases were open. Prime v. DexCom, Inc., docket 1:25-cv-08912, via CourtListener (court records). Nature of suit 850, company named as first defendant

After it was reported

After	Stock	S&P 500	Difference
7 days	+9.8%	+0.3%	+9.5%
30 days	+6.3%	+0.1%	+6.3%

Past results only. Not a forecast.

Source receipt

Record ID: 0001093557-26-000145
Filed / recorded: Aug 4, 2026, 8:38 PM UTC
Added to OQRO: Oct 2, 2026, 12:27 PM UTC
Parser: form4-xml-v1
Data quality: Verified: identifiers matched exactly
Issuer: DEXCOM INC
Issuer CIK: 1093557
Ticker: DXCM
Reporting person: Mark G Foletta
Relationship: Director
Security: Common Stock
Table: Non-derivative (Table I)
Transaction date: Jul 31, 2026
Transaction code: S
Shares / units: 2,000
Price per share: $80.00
Acquired / disposed: Disposed (D)
Shares owned after: 50,852
Ownership form: Indirect — by Trust
Amendment: No

Footnotes from the filing

On March 13, 2026, The Foletta Family Trust DTD 1/30/2015 (the "Trust") adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by the Trust. The shares set forth above were sold pursuant to the 10b5-1 Plan.
Shares are held by The Foletta Family Trust DTD 1/30/2015, with respect to which the Reporting Person is a trustee.